Compare ECF & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECF | RZLT |
|---|---|---|
| Founded | 1986 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.1M | 187.3M |
| IPO Year | N/A | N/A |
| Metric | ECF | RZLT |
|---|---|---|
| Price | $11.68 | $1.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.33 |
| AVG Volume (30 Days) | 57.7K | ★ 13.0M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 6.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.02 | $1.07 |
| 52 Week High | $8.91 | $11.46 |
| Indicator | ECF | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 46.79 | 24.57 |
| Support Level | $11.31 | $1.07 |
| Resistance Level | $12.05 | $2.25 |
| Average True Range (ATR) | 0.20 | 0.60 |
| MACD | -0.03 | -0.77 |
| Stochastic Oscillator | 45.95 | 7.13 |
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.